302
Participants
Start Date
March 8, 2016
Primary Completion Date
June 7, 2017
Study Completion Date
November 29, 2017
LCZ696 (sacubitril/valsartan)
All patients were treated with the LCZ696 (sacubitril and valsartan) tablets
Novartis Investigative Site, Edmonton
Novartis Investigative Site, New Westminster
Novartis Investigative Site, Vancouver
Novartis Investigative Site, Winnipeg
Novartis Investigative Site, Moncton
Novartis Investigative Site, Moncton
Novartis Investigative Site, St. John's
Novartis Investigative Site, Burlington
Novartis Investigative Site, Cambridge
Novartis Investigative Site, Greater Sudbury
Novartis Investigative Site, Greater Sudbury
Novartis Investigative Site, London
Novartis Investigative Site, Mississauga
Novartis Investigative Site, Newmarket
Novartis Investigative Site, Newmarket
Novartis Investigative Site, Ottawa
Novartis Investigative Site, Peterborough
Novartis Investigative Site, Sarnia
Novartis Investigative Site, Scarborough Village
Novartis Investigative Site, Scarborough Village
Novartis Investigative Site, Toronto
Novartis Investigative Site, Waterloo
Novartis Investigative Site, Weston
Novartis Investigative Site, Greenfield Park
Novartis Investigative Site, Joliette
Novartis Investigative Site, Montreal
Novartis Investigative Site, Saint-Jean-sur-Richelieu
Novartis Investigative Site, Terrebonne
Novartis Investigative Site, Brossard
Novartis Investigative Site, Hamilton
Novartis Investigative Site, Québec
Novartis Investigative Site, Saint-Lambert
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY